Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
RELA
REST API REST API
Homo sapiens
RELA is differentially expressed in 280 experiments: 143 organism parts: cerebellum, prostate, ... (141 more);, 193 disease states: normal, control, ... (191 more);, 82 cell types 315 cell lines 36 compound treatments and 81 other conditions.
Synonyms p65, NFKB3
Orthologs rela (Danio rerio)   Rela (Rattus norvegicus)   A1XG22_BOVIN (Bos taurus)   Rela (Mus musculus)   Dif (Drosophila melanogaster)   dl (Drosophila melanogaster)   rela (Xenopus laevis)   A1XFH4_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term Toll signaling pathway, defense response to virus, cytosol, response to hydrogen peroxide, DNA binding, negative regulation of transcription, DNA-dependent, protein binding, regulation of transcription, DNA-dependent, cytokine-mediated signaling pathway, cytoplasm, innate immune response, protein complex, transcription, DNA-dependent, positive regulation of cell proliferation, negative regulation of apoptosis, protein N-terminus binding, response to stress, anti-apoptosis, transcription from RNA polymerase II promoter, transcription factor binding, sequence-specific DNA binding, identical protein binding, defense response, positive regulation of transcription from RNA polymerase II promoter, response to cAMP, response to bacterium, protein kinase binding, nucleus, response to lipopolysaccharide, aging, transcription factor complex, response to drug, chromatin binding, positive regulation of NF-kappaB transcription factor activity, nucleoplasm, cellular defense response, positive regulation of transcription, DNA-dependent, organ morphogenesis, negative regulation of insulin receptor signaling pathway, response to mechanical stimulus, ubiquitin protein ligase binding, positive regulation of I-kappaB kinase/NF-kappaB cascade, toll-like receptor 4 signaling pathway, response to cytokine stimulus, T cell receptor signaling pathway, hair follicle development, toll-like receptor signaling pathway, response to progesterone stimulus, positive regulation of chondrocyte differentiation, response to morphine, response to UV-B, response to interleukin-1, positive regulation of Schwann cell differentiation, response to inorganic substance, response to muramyl dipeptide, interspecies interaction between organisms, NF-kappaB binding, response to amino acid stimulus, toll-like receptor 3 signaling pathway, response to insulin stimulus, positive regulation of interleukin-12 biosynthetic process, inflammatory response, regulation of inflammatory response, liver development, response to organic substance, nerve growth factor receptor signaling pathway, toll-like receptor 2 signaling pathway, MyD88-dependent toll-like receptor signaling pathway, cellular response to lipopolysaccharide, nucleotide-binding oligomerization domain containing 2 signaling pathway, response to cobalamin, negative regulation of protein catabolic process, sequence-specific DNA binding transcription factor activity, MyD88-independent toll-like receptor signaling pathway, activating transcription factor binding, membrane protein intracellular domain proteolysis, ankyrin repeat binding, response to organic cyclic compound, transcription regulatory region DNA binding, repressing transcription factor binding, acetaldehyde metabolic process, toll-like receptor 1 signaling pathway, sequence-specific distal enhancer binding RNA polymerase II transcription factor activity, phosphate ion binding
InterPro Term RHD, NF_Rel_dor, IPT_TIG_rcpt
UniProt Accession Q96CP1, Q96F54, Q2TAM5, Q04206, B4E082, E9PNV4, E9PNK5, E9PN69, E9PMD5, E9PSE4, E9PRX2, E9PQS6, E9PI38, E9PJR1, E9PJZ9, E9PKH5, E9PKV4, E9PM47
Search EB-eye ENSG00000173039
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-22541, E-MTAB-24, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (35 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
MCF-7
3
E-GEOD-3529, E-GEOD-20081, E-GEOD-19639
HepG2
2
E-GEOD-21154, E-GEOD-7307
AGS
2
E-GEOD-15460, E-MTAB-37
MDA-MB-231
2
E-TABM-420, E-MTAB-62
ssMCF7
1
E-GEOD-5258
309 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-4219, E-GEOD-13909, ... (43 experiments)

Factor Value U/D Experiments
CD8+ T cell
3
E-AFMX-5, E-GEOD-19069, E-TABM-145
CD4+ T cell
1
3
E-GEOD-16190, E-AFMX-5, E-MTAB-24, E-TABM-145
partially reprogrammed human induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
macrophage
2
E-GEOD-22373, E-GEOD-5099
epithelial cell
1
2
E-MEXP-2034, E-GEOD-10797, E-GEOD-4483
centroblast
1
E-TABM-702
76 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (64 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-GEOD-96, E-MEXP-2034, E-GEOD-3868
choriocarcinoma
2
E-MTAB-37, E-MTAB-62
lung adenocarcinoma
2
E-MTAB-62, E-MTAB-37
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
glioblastoma
1
2
E-GEOD-4290, E-MTAB-37, E-MTAB-62
engineered invasive esophageal squamous cell carcinoma
1
E-GEOD-21293
187 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-15205, E-GEOD-697, E-GEOD-5099, E-GEOD-6462, ... (24 experiments)

Factor Value U/D Experiments
none
3
8
E-MEXP-1958, E-GEOD-2803, E-GEOD-412, E-TABM-127, E-MEXP-1269, ... (11 experiments)
control
2
E-GEOD-3284, E-GEOD-4006
placebo
2
E-MEXP-1335, E-MEXP-1327
interferon-gamma
1
E-GEOD-1925
filtered air
1
E-TABM-127
interferon alpha
1
E-GEOD-1740
30 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
75
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, E-GEOD-16363, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-860, E-GEOD-1563, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-1638, E-GEOD-20033, E-GEOD-3140, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-22541, E-TABM-147, E-GEOD-21138, E-GEOD-3013 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-6207, E-MTAB-73, E-GEOD-17385, E-GEOD-20847, E-MEXP-2340, ... (6 experiments)

Genotype
studied in E-GEOD-2466, E-GEOD-22593, E-GEOD-2292, E-TABM-868, E-GEOD-18005, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, ... (10 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, ... (31 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12254, E-MEXP-561, E-GEOD-980, ... (6 experiments)

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-22309, E-GEOD-21750

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-1703, E-MEXP-1509, E-GEOD-1676, E-MEXP-548, E-GEOD-3697, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494

Test result
studied in E-GEOD-1926, E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541

Vehicle
studied in E-GEOD-5258

Processing time: 0.427 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM